The relationship between gene polymorphisms and type 2 diabetes susceptibility and anti-diabetic drug therapy efficacy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-CCC-09000406

Enrollment

Unknown

Registered

2009-05-13

Start date

2006-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

control group:no

Type 2 Diabetes group:treated with rosiglitazone or Repaglinide to control blood glucose according to the genotype

Eligibility

Sex/Gender

Male

Age

20 Years to 79 Years

Inclusion criteria

Inclusion criteria: Diagnostic criteria for diabetes based on 1997 American Diabetes Association diagnostic criteria of DM: fasting plasma glucose (FPG)>=7.0mmol/L or postprandial glucose (PPG)>=11.1 mmol/L

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes, gestational diabetes, hypertension and severe liver and kidney disease were excluded

Design outcomes

Primary

Measure	Time frame
ADRB3, adiponectin, LEPTIN, TNFa, VISTATIN, RBP4, PPAR, PGC, KCNJ11 and TCF7L2 gene;	—

Countries

China

Contacts

Public ContactZhaoqian Liu, Qiong Huang, Ming Yu, Feifeng Shen

liuzhaoqian63@126.com+86 0731 4805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026